Arcus Biosciences, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NYSE
Gilead Sciences, Inc. has filed an Amendment No. 6 to Schedule 13D, updating its beneficial ownership in Arcus Biosciences, Inc. to 25.6% of outstanding common stock.
NYSE
SCHEDULE: Gilead Sciences' Option to Increase Stake in Arcus Biosciences Expires, Maintaining 29.7% Ownership
Gilead Sciences, Inc.'s option to acquire additional shares in Arcus Biosciences, Inc., potentially increasing its stake to 35%, expired on July 13, 2025, leaving its beneficial ownership at 29.7%.
NYSE
SCHEDULE 13D/A: Gilead Sciences Boosts Stake in Arcus Biosciences to 35% Through Latest Public Offering and Strategic Option
Gilead Sciences, Inc. has increased its beneficial ownership in Arcus Biosciences, Inc. to 35% through a series of stock purchases, including a recent public offering, reinforcing their strategic collaboration.
NYSE
SCHEDULE 13D/A: Gilead Sciences Solidifies Strategic Stake in Arcus Biosciences, Reaching 35% Ownership
Gilead Sciences, Inc. has significantly increased its beneficial ownership in Arcus Biosciences, Inc. to 35% through a series of strategic share purchases and option exercises, reinforcing their ongoing collaboration.